Ranbaxy Expands US Production Capacity Because of Import Alert
“Because of the U.S. FDA ban, we are currently working on site switches to alternative sources in-house and also evaluating U.S. manufacturing capacity expansion in our existing facilities,” Ranbaxy CEO Malvinder Singh said last month during the company’s year-end earnings call.
“We are working on other options for additional FDA-approved facilities, either by moving our products to other parties or also evaluating opportunities to acquire FDA-approved manufacturing capacity,” Singh continued.
The FDA issued two warning letters and the import alert last fall.
Drug GMP Report